182 related articles for article (PubMed ID: 15996504)
1. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France.
Fautrel B; Woronoff-Lemsi MC; Ethgen M; Fein E; Monnet P; Sibilia J; Wendling D
Joint Bone Spine; 2005 Dec; 72(6):550-6. PubMed ID: 15996504
[TBL] [Abstract][Full Text] [Related]
2. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
Weycker D; Yu EB; Woolley JM; Oster G
Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
[TBL] [Abstract][Full Text] [Related]
4. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
5. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
6. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
Mora C; González A; Díaz J; Quintana G
Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of rheumatoid arthritis (RA) biotherapies in France.
Maravic M
Joint Bone Spine; 2010 Jul; 77(4):319-24. PubMed ID: 20493751
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
9. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
10. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)].
Rubio-Terrés C; Ordovás Baines JP; Pla Poblador R; Martínez Nieto C; Sánchez Garre MJ; Rosado Souvirón MA; Sierra Muñoz A; Sánchez Mateo M;
Farm Hosp; 2007; 31(2):78-92. PubMed ID: 17590116
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
Spalding JR; Hay J
Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
[TBL] [Abstract][Full Text] [Related]
12. The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.
Sørensen J; Andersen LS
Pharmacoeconomics; 2005; 23(3):289-98. PubMed ID: 15836009
[TBL] [Abstract][Full Text] [Related]
13. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Ollendorf DA; Peterson AN; Doyle J; Huse DM
Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
[TBL] [Abstract][Full Text] [Related]
14. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
15. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
[TBL] [Abstract][Full Text] [Related]
16. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
Kobelt G; Eberhardt K; Geborek P
Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
[TBL] [Abstract][Full Text] [Related]
19. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]